top of page
Search

MYOCARDITIS, PERICARDITIS ( EN HARTFALEN )

Studie op 23 miljoen mensen :

Key Points Question Is SARS-CoV-2 messenger RNA (mRNA) vaccination associated with risk of myocarditis? Findings In a cohort study of 23.1 million residents across 4 Nordic countries, risk of myocarditis after the first and second doses of SARS-CoV-2 mRNA vaccines was highest in young males aged 16 to 24 years after the second dose. For young males receiving 2 doses of the same vaccine, data were compatible with between 4 and 7 excess events in 28 days per 100 000 vaccinees after second-dose BNT162b2, and between 9 and 28 per 100 000 vaccinees after second-dose mRNA-1273. Meaning The risk of myocarditis in this large cohort study was highest in young males after the second SARS-CoV-2 vaccine dose, and this risk should be balanced against the benefits of protecting against severe COVID-19 disease. Results Among 23 122 522 Nordic residents (81% vaccinated by study end; 50.2% female), 1077 incident myocarditis events and 1149 incident pericarditis events were identified. Within the 28-day period, for males and females 12 years or older combined who received a homologous schedule, the second dose was associated with higher risk of myocarditis, with adjusted IRRs of 1.75 (95% CI, 1.43-2.14) for BNT162b2 and 6.57 (95% CI, 4.64-9.28) for mRNA-1273. Among males 16 to 24 years of age, adjusted IRRs were 5.31 (95% CI, 3.68-7.68) for a second dose of BNT162b2 and 13.83 (95% CI, 8.08-23.68) for a second dose of mRNA-1273, and numbers of excess events were 5.55 (95% CI, 3.70-7.39) events per 100 000 vaccinees after the second dose of BNT162b2 and 18.39 (9.05-27.72) events per 100 000 vaccinees after the second dose of mRNA-1273. Estimates for pericarditis were similar. Conclusions and Relevance Results of this large cohort study indicated that both first and second doses of mRNA vaccines were associated with increased risk of myocarditis and pericarditis. For individuals receiving 2 doses of the same vaccine, risk of myocarditis was highest among young males (aged 16-24 years) after the second dose. These findings are compatible with between 4 and 7 excess events in 28 days per 100 000 vaccinees after BNT162b2, and between 9 and 28 excess events per 100 000 vaccinees after mRNA-1273. This risk should be balanced against the benefits of protecting against severe COVID-19 disease. “Results of this large cohort study indicated that both first and second doses of mRNA vaccines were associated with increased risk of myocarditis and pericarditis. “For individuals receiving two doses of the same vaccine, risk of myocarditis was highest among young males after the second dose. These findings are compatible with between 4 and 7 excess events in 28 days per 100,000 vaccinees after BNT162b2 [the BioNTech/Pfizer vaccine], and between 9 and 28 excess events per 100,000 vaccinees after mRNA-1273 [the Moderna vaccine].” This risk should be balanced against the benefits of protecting against severe COVID-19 disease.

Hoeveel studies moeten er nog verschijnen vooraleer de overheid, de experten en al wie rechtstreeks of onrechtstreeks betrokken is bij de vaccinatiecampagne ( waaronder alle artsen, de ziekenhuizen, de scholen ... ) beseffen en toegeven dat de Covid19 vaccins een fenomenale fout is (geweest) en veel schade en doden veroorzaakt ?

Bij de aanvang van de vaccinatiecampagne en nadien nog vaak is gesteld " elke corona dode is er één teveel ". Dat is juist. Maar blijkbaar zijn vaccin doden en mensen ( waaronder veel jongeren en sportlui ) die plots dood neervallen of hartziekten zoals myocarditis en pericarditis oplopen, blijkbaar geen probleem ? Dat er een risico is op deze aandoeningen werd zowel door het EMA als door Pfizer zelve toegegeven en in kaart gebracht. Waarom heeft de overheid bij het volk toch aangedrongen om zich te laten vaccineren ? Eerst een dubbele vaccinatie onder de valse belofte dat dit een hoge bescherming zou bieden ? Vervolgens een derde boostershot en thans een 4de prik ? De EU heeft in juni 2021 ( ! ) meerdere efficiënte corona medicijnen goedgekeurd ( 5 uit een lijst van 10 ). De " coronapil " is al ettelijke maanden beschikbaar op de markt ? Waarom wordt daar in alle talen over gezwegen alsof dit medicijn niet bestaat ? https://jamanetwork.com/journals/jamacardiology/fullarticle/2791253




1 view0 comments
bottom of page